Mumbai, India: Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) after closure of the U.S. FDA inspection of its Nagpur, India facility.
The inspection for the facility was carried out by the U.S. FDA between January 6, 2020 and January 10, 2020. Commenting on the receipt of the EIR, Nilesh Gupta, Managing Director, Lupin said, “We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility.
We remain committed to enhancing compliance and quality standards across all our manufacturing sites.”
Also read: Dr Reddy’s Labs gets EIR from USFDA